FN2 Earnings Intelligence
Regeneron Pharmaceuticals, Inc. income statement (quarterly)
Regeneron Pharmaceuticals, Inc. (REGN) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $2,011.8 | $3,090.2 | $1,995.8 | $2,506.4 | $2,962.6 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $3,720.7 | $3,028.7 | $3,675.6 | $3,754.3 | $3,605.4 | $3,816.3 | $4,180.7 |
| % Growth | - | - | - | - | - | 3.8% | 11.4% |
| Gross Profit | $3,458.4 | $2,763.2 | $3,400 | $3,473.3 | $3,232 | - | - |
| % Margin | 93.0% | 91.2% | 92.5% | 92.5% | 89.6% | - | - |
| EBITDA | - | $718.6 | - | - | $766.1 | - | - |
| % Margin | - | 23.7% | - | - | 21.2% | - | - |
| Net Income | $1,340.6 | $808.7 | $1,391.6 | $1,460 | $727.2 | - | - |
| % Margin | 36.0% | 26.7% | 37.9% | 38.9% | 20.2% | - | - |
| Diluted EPS | $11.54 | $7.27 | $12.81 | $13.62 | $6.75 | $10.21 | $13.07 |
| % Growth | - | - | - | - | - | -20.3% | -4.0% |
| Operating Cash Flow | - | $1,045.1 | - | - | $1,078.9 | - | - |
| CapEx | - | $229.3 | - | - | $230.6 | - | - |
| Free Cash Flow | - | $815.8 | - | - | $848.3 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $3,720.7 | $3,028.7 | $3,675.6 | $3,754.3 | $3,605.4 | $3,816.3 | $4,180.7 |
| Gross Profit | $3,458.4 | $2,763.2 | $3,400 | $3,473.3 | $3,232 | - | - |
| EBITDA | - | $718.6 | - | - | $766.1 | - | - |
| Net Income | $1,340.6 | $808.7 | $1,391.6 | $1,460 | $727.2 | - | - |
| Diluted EPS | $11.54 | $7.27 | $12.81 | $13.62 | $6.75 | $10.21 | $13.07 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2,011.8 | $3,090.2 | $1,995.8 | $2,506.4 | $2,962.6 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $1,984 | $1,984.8 | $1,985.1 | $1,985.5 | $1,986.2 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | $1,045.1 | - | - | $1,078.9 |
| Capital Expenditure | - | $229.3 | - | - | $230.6 |
| Free Cash Flow | - | $815.8 | - | - | $848.3 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 93.0% | 91.2% | 92.5% | 92.5% | 89.6% |
| EBITDA Margin | - | 23.7% | - | - | 21.2% |
| Net Margin | 36.0% | 26.7% | 37.9% | 38.9% | 20.2% |
| FCF Margin | - | 26.9% | - | - | 23.5% |
| Diluted EPS Growth | - | - | - | - | - |